학술논문

European data sources for computing burden of (potential) vaccine-preventable diseases in ageing adults.
Document Type
Journal Article
Source
BMC Infectious Diseases. 4/13/2021, Vol. 21 Issue 1, p1-9. 9p.
Subject
*AGE factors in disease
*PNEUMOCOCCAL pneumonia
*QUALITY-adjusted life years
*AGE groups
*ADULTS
*BRONCHIOLITIS
*PNEUMONIA-related mortality
*PNEUMONIA
*DISEASE incidence
*AGING
*NOROVIRUS diseases
*ECONOMIC aspects of diseases
*RESPIRATORY syncytial virus infections
Language
ISSN
1471-2334
Abstract
Background: To guide decision-making on immunisation programmes for ageing adults in Europe, one of the aims of the Vaccines and InfecTious diseases in the Ageing popuLation (IMI2-VITAL) project is to assess the burden of disease (BoD) of (potentially) vaccine-preventable diseases ((P)VPD). We aimed to identify the available data sources to calculate the BoD of (P)VPD in participating VITAL countries and to pinpoint data gaps. Based on epidemiological criteria and vaccine availability, we prioritized (P) VPD caused by Extra-intestinal pathogenic Escherichia coli (ExPEC), norovirus, respiratory syncytial virus, Staphylococcus aureus, and pneumococcal pneumonia.Methods: We conducted a survey on available data (e.g. incidence, mortality, disability-adjusted life years (DALY), quality-adjusted life years (QALY), sequelae, antimicrobial resistance (AMR), etc.) among national experts from European countries, and carried out five pathogen-specific literature reviews by searching MEDLINE for peer-reviewed publications published between 2009 and 2019.Results: Morbidity and mortality data were generally available for all five diseases, while summary BoD estimates were mostly lacking. Available data were not always stratified by age and risk group, which is especially important when calculating BoD for ageing adults. AMR data were available in several countries for S. aureus and ExPEC.Conclusion: This study provides an exhaustive overview of the available data sources and data gaps for the estimation of BoD of five (P) VPD in ageing adults in the EU/EAA, which is useful to guide pathogen-specific BoD studies and contribute to calculation of (P)VPDs BoD. [ABSTRACT FROM AUTHOR]